All Stories

  1. Orthostatic hypotension and acute cognitive dysfunction in Parkinson’s disease: insights from functional near-infrared spectroscopy
  2. Eating Disorders and Parkinson's Disease—1: Comorbidities, Neurobiology, and Family History
  3. Eating Disorders and Parkinson’s Disease - 1: Comorbidities, Neurobiology and Family History
  4. Eating Disorders and Parkinson’s Disease - 2: Population Burden, Genetic Epidemiology and Shared Genomics
  5. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies
  6. Characteristics and mechanisms of cognitive impairment in Parkinson disease
  7. An Alternative Approach to the Finger‐Tapping Test in Parkinsonian Patients: Finger to Crease Instead of Finger to Tip
  8. Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease
  9. Progressive Supranuclear Palsy—A Global Review
  10. Author Correction: Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
  11. Early Subtypes and Progressions of Progressive Supranuclear Palsy: A Data-Driven Brain Bank Study
  12. Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
  13. Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein
  14. T cell responses towards PINK1 and α-synuclein are elevated in prodromal Parkinson’s disease
  15. Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells
  16. Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease
  17. Diagnosing primary lateral sclerosis: a clinico-pathological study
  18. Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration
  19. Association of CSF α-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy Bodies
  20. Why Crafting a Compelling Abstract Is Important to Summarize Research Findings
  21. Biosensor Strip for Rapid On‐site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease
  22. Biosensor Strip for Rapid On‐site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease
  23. PINK1 is a target of T cell responses in Parkinson’s disease
  24. Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration
  25. Nicked tRNAs are stable reservoirs of tRNA halves in cells and biofluids
  26. CBD diagnostic criteria: exclusions as important as inclusions
  27. Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies
  28. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
  29. Nicked tRNAs are stable reservoirs of tRNA halves in cells and biofluids
  30. Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology
  31. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments
  32. Physician‐Assisted Dying: Access and Utilization in Patients with Movement Disorders
  33. Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders
  34. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
  35. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism
  36. Orthostatic hypotension preceding dementia with Lewy bodies by over 15 years: a clinicopathologic case report
  37. Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?
  38. Hypertension and progressive supranuclear palsy
  39. Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability
  40. End of life planning in parkinsonian diseases
  41. The virtual reality of Parkinson's disease freezing of gait: A systematic review
  42. Progress in the treatment of Parkinson-Plus syndromes
  43. Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions
  44. Therapeutic options for Progressive Supranuclear Palsy including investigational drugs
  45. The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy
  46. Which ante mortem clinical features predict progressive supranuclear palsy pathology?
  47. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
  48. Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease
  49. Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study
  50. Understanding falls in progressive supranuclear palsy
  51. Progression of brain atrophy in PSP and CBS over 6 months and 1 year
  52. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale
  53. Abolishing the 1-year rule: How much evidence will be enough?
  54. Environmental Exposures and Parkinson’s Disease
  55. Cognitive functioning in individuals with Parkinson’s disease and traumatic brain injury: A longitudinal study
  56. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy
  57. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials
  58. Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study
  59. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease
  60. α-synuclein genetic variability: A biomarker for dementia in Parkinson disease
  61. The new definition and diagnostic criteria of Parkinson's disease
  62. Technology in Parkinson's disease: Challenges and opportunities
  63. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy
  64. Relationship between uric acid levels and progressive supranuclear palsy
  65. Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study
  66. Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy
  67. Progressive supranuclear palsy: progression and survival
  68. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy
  69. Structural MRI Correlates of Episodic Memory Processes in Parkinson’s Disease Without Mild Cognitive Impairment
  70. Swallowing disturbances in the corticobasal syndrome
  71. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis
  72. Head injury exposure in PSP: a case-control study
  73. MDS clinical diagnostic criteria for Parkinson's disease
  74. MDS research criteria for prodromal Parkinson's disease
  75. The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease
  76. Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)
  77. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy
  78. Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report
  79. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
  80. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases
  81. Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy
  82. The Wearable Multimodal Monitoring System: A Platform to Study Falls and Near-Falls in the Real-World
  83. Correcting for Demographic Variables on the Modified Telephone Interview for Cognitive Status
  84. A disposable electrochemical biosensor for l-DOPA determination in undiluted human serum
  85. Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)
  86. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
  87. Faculty Opinions recommendation of Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.
  88. P3‐165: MILD COGNITIVE IMPAIRMENT AMONG PARKINSON'S DISEASE SUBJECTS IN THE UNIFORM DATA SET
  89. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
  90. Progressive Supranuclear Palsy and Corticobasal Degeneration
  91. Corticobasal Degeneration
  92. The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment
  93. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status
  94. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
  95. Cognition in movement disorders: Where can we hope to be in ten years?
  96. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease
  97. Instrumental activities of daily living are impaired in Parkinson’s disease patients with mild cognitive impairment.
  98. Rate of decline in progressive supranuclear palsy
  99. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy
  100. Dissociation of Neural Mechanisms for Intersensory Timing Deficits in Parkinson’s Disease
  101. Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy
  102. Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria
  103. Behavioral abnormalities in progressive supranuclear palsy
  104. Faculty Opinions recommendation of Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
  105. Primary Health Care Providers' Knowledge Gaps on Parkinson's Disease
  106. Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson’s disease
  107. Parkinsonian Syndromes
  108. Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease
  109. Neuropsychiatric and cognitive disorders in other parkinsonian disorders
  110. Faculty Opinions recommendation of The natural history of multiple system atrophy: a prospective European cohort study.
  111. P4–096: APOE‐ɛ4 and clinical progression in Parkinson's disease
  112. The meaning of a “hippo” response on the Montreal Cognitive Assessment in Parkinson's disease
  113. Measuring mild cognitive impairment in patients with Parkinson's disease
  114. Criteria for the diagnosis of corticobasal degeneration
  115. Functional impairment in progressive supranuclear palsy
  116. White-Matter Changes Correlate with Cognitive Functioning in Parkinson’s Disease
  117. Long-duration Parkinson's disease: Role of lateralization of motor features
  118. Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease
  119. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease
  120. Toward magnetic resonance imaging biomarkers for progressive supranuclear palsy and multisystem atrophy
  121. Faculty Opinions recommendation of Pareidolias: complex visual illusions in dementia with Lewy bodies.
  122. Faculty Opinions recommendation of Parkinson subtypes progress differently in clinical course and imaging pattern.
  123. Executive Dysfunction Is the Primary Cognitive Impairment in Progressive Supranuclear Palsy
  124. Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines
  125. The pill questionnaire in a nondemented Parkinson's disease population
  126. Examining the Motor Phenotype of Patients with Both Essential Tremor and Parkinson’s Disease
  127. Faculty Opinions recommendation of Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
  128. Pan-American Consortium of Multiple System Atrophy. Preliminary Report (P06.079)
  129. Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study
  130. Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2
  131. Phosphorylated  -Synuclein in Parkinson's Disease
  132. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
  133. Annonacin in Asimina triloba fruit: Implication for neurotoxicity
  134. Roles of Education and IQ in Cognitive Reserve in Parkinson’s Disease-Mild Cognitive Impairment
  135. Faculty Opinions recommendation of Quantitative EEG as a predictive biomarker for Parkinson disease dementia.
  136. Cytokine expression and microglial activation in progressive supranuclear palsy
  137. Faculty Opinions recommendation of α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.
  138. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome
  139. Parkinsonism and Frontotemporal Dementia: The Clinical Overlap
  140. Progressive Supranuclear Palsy and Corticobasal Degeneration
  141. Brain-Lung-Thyroid Disease
  142. Copy Number Variation in Familial Parkinson Disease
  143. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
  144. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
  145. Faculty Opinions recommendation of Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.
  146. Milestones in atypical and secondary Parkinsonisms
  147. Assessment of cognition in early dementia
  148. Woman with gait impairment and difficulty reading
  149. Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
  150. A recommended scale for cognitive screening in clinical trials of Parkinson's disease
  151. Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson’s disease
  152. Faculty Opinions recommendation of Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.
  153. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease
  154. Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease
  155. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy
  156. Faculty Opinions recommendation of Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
  157. H1/H1 genotype influences symptom severity in corticobasal syndrome
  158. Faculty Opinions recommendation of Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.
  159. Bradykinesia
  160. Tauopathies
  161. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
  162. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
  163. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort
  164. Genomewide association study for onset age in Parkinson disease
  165. Faculty Opinions recommendation of Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.
  166. Faculty Opinions recommendation of Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study.
  167. Faculty Opinions recommendation of A controlled trial of antidepressants in patients with Parkinson disease and depression.
  168. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
  169. Review article Progressive supranuclear palsy revisited
  170. Reply: Corticobasal syndrome with Alzheimer's disease pathology
  171. Parkinson’s Disease: An Overview of Pathogenesis
  172. Is it PD, PSP, CBD, DLB, or MSA?
  173. Faculty Opinions recommendation of Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
  174. Genomewide association study for susceptibility genes contributing to familial Parkinson disease
  175. The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study
  176. Faculty Opinions recommendation of Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.
  177. Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study
  178. Replication of association between ELAVL4 and Parkinson disease: the GenePD study
  179. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study
  180. Faculty Opinions recommendation of Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia.
  181. Progressive supranuclear palsy and corticobasal degeneration: similarities and differences
  182. Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
  183. Preface
  184. Current and future therapeutic approaches in progressive supranuclear palsy
  185. Biology and Neuropathology of Dementia in Syphilis and Lyme Disease
  186. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
  187. Clinical and Therapeutic Aspects of Dementia in Syphilis and Lyme Disease
  188. Clinical aspects and biology of normal pressure hydrocephalus
  189. Clinical aspects of Parkinson dementia
  190. Clinical symptoms in Alzheimer's disease
  191. History of Dementia
  192. Mild cognitive impairment
  193. Neuropathology and genetics of corticobasal degeneration
  194. Neuropathology of Pick body disease
  195. Neuropathology of Hereditary Forms of Frontotemporal Dementia and Parkinsonism
  196. Perspectives of Alzheimer's disease treatments
  197. Quality of Life in Dementias
  198. The Epidemiology of vascular dementia
  199. The Neuropathology of Vascular and Mixed Dementia and Vascular Cognitive Impairment
  200. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
  201. Update of atypical parkinsonian disorders
  202. Clinical diagnostic criteria for dementia associated with Parkinson's disease
  203. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II
  204. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I
  205. Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms
  206. Faculty Opinions recommendation of Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial.
  207. Faculty Opinions recommendation of Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
  208. Neurobiology of Progressive Supranuclear Palsy
  209. Unraveling progressive supranuclear palsy: from the bedsideback to the bench
  210. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD Study
  211. Alzheimer's disease presenting as corticobasal syndrome
  212. Measuring quality of life in PSP
  213. Faculty Opinions recommendation of Compulsive drug use linked to sensitized ventral striatal dopamine transmission.
  214. Atypical Parkinsonian Disorders--Clinical and Research Aspects * Edited by Irene Litvan * Human Press, 2005. ISBN 1-588-29-331-9. $175.00
  215. Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease
  216. Current and future treatments in progressive supranuclear palsy
  217. Penguins and hummingbirds: Midbrain atrophy in progressive supranuclear palsy
  218. Faculty Opinions recommendation of Substantia nigra tangles are related to gait impairment in older persons.
  219. Faculty Opinions recommendation of A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
  220. Book Review Drug Induced Movement Disorders Second edition. Edited by Stewart A. Factor, Anthony E. Lang, and William J. Weiner. 466 pp. Malden, Mass., Blackwell Futura, 2005. $120. 1-4051-2619-1
  221. Lrrk2 and Lewy body disease
  222. Midbrain atrophy in progressive supranuclear palsy: comparison of two dimensional planimetric- with three dimensional volumetric measurements
  223. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study
  224. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
  225. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy
  226. Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski’s description of PSP 40 years ago and Albert’s delineation of the subcortical dementia 30 years ago
  227. “Applause sign” helps to discriminate PSP from FTD and PD
  228. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome
  229. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response
  230. Atypical Parkinsonian Disorders
  231. What is an Atypical Parkinsonian Disorder?
  232. Progressive Supranuclear Palsy
  233. Progressive Supranuclear Palsy and Corticobasal Degeneration
  234. Update on progressive supranuclear palsy
  235. ATYPICAL PARKINSONIAN DISORDERS
  236. Diagnostic issues in non-AD dementias
  237. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration
  238. Verifying Clinical Criteria for Parkinsonian Disorders with CART Decision Trees
  239. Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?
  240. Update on epidemiological aspects of progressive supranuclear palsy
  241. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease
  242. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
  243. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy
  244. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia
  245. Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?
  246. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
  247. Freezing of gait in postmortem‐confirmed atypical parkinsonism
  248. Mitochondrial Dysfunction in Cybrid Lines Expressing Mitochondrial Genes from Patients with Progressive Supranuclear Palsy
  249. Corticobasal Degeneration and Related Disorders
  250. Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease
  251. Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders
  252. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
  253. Biased responding: a case series demonstrating a relationship between somatic symptoms and impaired recognition memory performance for traumatic brain injured individuals
  254. Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype
  255. Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy
  256. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype
  257. Therapy and management of frontal lobe dementia patients
  258. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy
  259. An open letter to the Committee on The Nobel Prize in Medicine
  260. Impairment of eyeblink classical conditioning in progressive supranuclear palsy
  261. Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders
  262. Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease
  263. Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease
  264. Diagnosis and Management of Progressive Supranuclear Palsy
  265. The FAB
  266. Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study
  267. Research goals in progressive supranuclear palsy
  268. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease
  269. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy
  270. Language disturbances in corticobasal degeneration
  271. Pupillary diameter assessment: Need for a graded scale
  272. Frontal Assessment Battery
  273. Importance of deficits in executive functions
  274. Evaluation of surgery for Parkinson’s disease
  275. Progression of falls in postmortem-confirmed Parkinsonian disorders
  276. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study
  277. Atypical parkinsonism in the French West Indies
  278. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias
  279. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration
  280. Recent advances in atypical parkinsonian disorders
  281. Effects of Physostigmine on Swallowing and Oral Motor Functions in Patients with Progressive Supranuclear Palsy: A Pilot Study
  282. Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
  283. Clinicopathologic Case Report
  284. Consensus statement on the diagnosis of multiple system atrophy
  285. Ideomotor apraxia in progressive supranuclear palsy: A case study
  286. Ideomotor apraxia in progressive supranuclear palsy: A case study
  287. A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration
  288. Nuevas perspectivas en la enfermedad de Parkinson
  289. Consensus statement on the diagnosis of multiple system atrophy
  290. Parkinsonian Features
  291. Caregiving in progressive supranuclear palsy
  292. Neuropsychiatric features of corticobasal degeneration
  293. Neuropsychiatric Assessment of Patients With Hyperkinetic and Hypokinetic Movement Disorders
  294. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study
  295. Reliability of the NINDS Myotatic Reflex Scale
  296. Reliability of the NINDS Myotatic Reflex Scale
  297. Pharmacological Therapy in Progressive Supranuclear Palsy
  298. Is EEG useful in the differential diagnosis of parkinsonism?
  299. Apathy Is Not Depression
  300. Dysfunction of Ib (Autogenic) spinal inhibition in patients with progressive supranuclear palsy
  301. Clinical and Genetic Aspects of Progressive Supranuclear Palsy
  302. Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies
  303. Progressive supranuclear palsy
  304. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy
  305. Apolipoprotein Eepsilon4 (Epsilon) Allele Does Not Affect the Onset or Symptom Severity in Progressive Supranuclear Palsy
  306. What are the Obstacles for an Accurate Clinical Diagnosis of Pick's disease?
  307. Methodological and Research Issues in the Evaluation of Biological Diagnostic Markers for Alzheimer’s Disease
  308. Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI). 22The ...
  309. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination
  310. PROGRESSIVE SUPRANUCLEAR PALSY
  311. Limb shaking in multiple system atrophy
  312. Progressive supranuclear gaze palsy is in linkage disequilibrium with theτ and not the α-synuclein gene
  313. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration
  314. What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?
  315. The clinical and pathologic hallmarks of progressive supranuclear palsy
  316. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism
  317. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study
  318. Characterizing swallowing abnormalities in progressive supranuclear palsy
  319. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study
  320. Accuracy of the Clinical Diagnosis of Corticobasal Degeneration: A Clinicopathologic Study
  321. REPLY FROM THE AUTHORS
  322. A Reappraisal of Reliability and Validity Studies in Stroke
  323. Neuropsychiatric aspects of progressive supranuclear palsy
  324. Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?
  325. Reliability of the NINDS Myotatic Reflex Scale
  326. Preserved cognitive processes in cerebellar degeneration
  327. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop
  328. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
  329. Visualizing Cortical Activation during Mental Calculation with Functional MRI
  330. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
  331. Progressive supranuclear palsy: a clinicopathological study of 21 cases
  332. 641 Accuracy of the clinical diagnosis of pick's disease
  333. Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders
  334. What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?
  335. Neuropsychological Features of Progressive Supranuclear Palsy
  336. What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia?
  337. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
  338. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy
  339. Cognitive disturbances in progressive supranuclear palsy
  340. Cholinergic approaches to the treatment of progressive supranuclear palsy
  341. Cerebellar cognition
  342. Cognitive planning deficit in patients with cerebellar atrophy
  343. CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy
  344. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
  345. Progressive supranuclear palsy
  346. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.
  347. Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy
  348. Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function
  349. Selective deficits in cognition and memory in high-functioning parkinsonian patients.
  350. Frontal Lobe Function in Progressive Supranuclear Palsy
  351. Implicit Learning in Patients with Alzheimer's Disease
  352. Physostigmine treatment of progressive supranuclear palsy
  353. Memory Impairment in Patients With Progressive Supranuclear Palsy
  354. Multiple Memory Deficits in Patients With Multiple Sclerosis
  355. Slowed Information Processing in Multiple Sclerosis
  356. Unilateral left cerebral deterioration documented by CT, MRI, and neuropsychological studies: A possible case of pick's disease
  357. Behcet's syndrome masquerading as tumor
  358. Does reversed laterality really exist in dextrals? A case study
  359. Agitation and Apathy in Hyper- and Hypokinetic Movement Disorders
  360. Measuring quality of life in progressive supranuclear palsy
  361. Management of cognitive impairment in Parkinson's disease
  362. Faculty of 1000 evaluation for Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.
  363. Case Studies